Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies

医学 美罗华 多神经根神经病 内科学 临床终点 前瞻性队列研究 外科 胃肠病学 临床试验 免疫学 格林-巴利综合征 淋巴瘤
作者
Pietro Emiliano Doneddu,Dario Cocito,Raffaella Fazio,Luana Benedetti,Erdita Peci,Giuseppe Liberatore,Yuri Falzone,Francesco Germano,Francesca Gallia,Claudia Giannotta,Cinta Lleixà,Elisa Bianchi,Eduardo Nobile‐Orazio
出处
期刊:Journal of Neurology, Neurosurgery, and Psychiatry [BMJ]
卷期号:95 (9): 838-844 被引量:23
标识
DOI:10.1136/jnnp-2023-332844
摘要

BACKGROUND: To evaluate the efficacy of rituximab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients not responding to conventional immune therapies. METHODS: An open-label, prospective exploratory study was conducted with intravenous rituximab on 17 CIDP patients who had not responded to at least two first-line therapies. The primary endpoint was to determine the proportion of patients who showed improvement 6 months after rituximab therapy. The percentage of responders to rituximab, along with a 95% CI, was reported and compared with the 30% response rate after other immunosuppressive drugs previously documented in the literature. RESULTS: 13 of the 17 treated patients (76.5%) showed improvement at 6 months (95% CI 50.1 to 93.2). Among the 14 patients who completed the 12-month follow-up (2 were lost to follow-up after showing improvement at months 8 and 10, and 1 deteriorated at 6 months), 13 (92.9%) demonstrated improvement at 12 months (95% CI 66.1 to 99.8). Nerve conduction parameters improved by at least 20% in two nerves in 6 out of 15 (40%) patients at 6 months and in 7 out of 13 (53.9%) at 12 months. None of the treated patients withdrew from the study due to side effects. There was a significant reduction of circulating CD19+ cells 15 days, 2, 6 and 12 months after treatment. CONCLUSION: Rituximab seems to be a safe therapy in most patients with CIDP not responding to conventional immune therapies. The high percentage of patients who improved in this study suggests a possible positive effect of rituximab which is worth investigating in future randomised controlled clinical trials. TRIAL REGISTRATION NUMBER: NCT05877040.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无限之双发布了新的文献求助10
1秒前
失眠孤兰发布了新的文献求助10
1秒前
自由的从蓉关注了科研通微信公众号
2秒前
chenjianshu的应助被特柠溪采纳,获得10
3秒前
3秒前
nature发布了新的文献求助10
4秒前
xfy发布了新的文献求助200
5秒前
6秒前
慕遥的应助被净心采纳,获得10
6秒前
丘比特的应助被失眠孤兰采纳,获得10
6秒前
英姑的应助被失眠孤兰采纳,获得10
6秒前
7秒前
含蓄雨柏完成签到,获得积分10
7秒前
Nole的应助被严肃的梨采纳,获得10
7秒前
鸡血红发布了新的文献求助10
8秒前
9秒前
10秒前
海盗船长发布了新的文献求助10
10秒前
11秒前
幽默山槐完成签到,获得积分10
11秒前
11秒前
从容雅柏完成签到,获得积分10
11秒前
张顺完成签到,获得积分10
11秒前
不想科研的科研人完成签到,获得积分10
11秒前
12秒前
Sereilla完成签到,获得积分10
12秒前
Cherry完成签到 ,获得积分10
13秒前
lynyee关注了科研通微信公众号
13秒前
14秒前
123发布了新的文献求助10
14秒前
14秒前
爆米花的应助被无限之双采纳,获得10
14秒前
15秒前
15秒前
三斤鱼完成签到,获得积分10
15秒前
15秒前
不安晓曼发布了新的文献求助10
16秒前
16秒前
李之恒完成签到,获得积分10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193425
求助须知:如何正确求助?哪些是违规求助? 9579620
关于积分的说明 21866505
捐赠科研通 7793025
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484128